PCV/mycoplasma hyopneumoniae/lawsonia intracellularis combination vaccine
AssigneeZoetis Services LLC
InventorsGregory P. Nitzel, Jeffrey E. Galvin, John Keith Garrett, James R. Kulawik, II, Tracy L. Ricker, Megan Marie Smutzer
Life of this patent
Estimating the term…
Abstract
This invention provides a multivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a Lawsonia intracellularis antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
Claims22
A multivalent immunogenic composition comprising a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation;
- a porcine circovirus type 2 (PCV2) antigen;
- and a Lawsonia intracellularis antigen, wherein the soluble portion of the M.hyo preparation comprises M.hyo-specific soluble protein antigens and is separated from insoluble cellular material and substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.
A kit comprising:
- a bottle comprising an immunogenic composition including the soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation, a PCV2 antigen, and a Lawsonia intracellularis antigen, wherein the soluble portion of the M.hyo preparation comprises M.hyo-specific soluble protein antigens and is separated from insoluble cellular material and substantially free of both (i) IgG and (ii) antigen/immunoglobulin immunocomplexes.
A method for preparing an immunogenic composition, the method comprising:
- i) culturing M.hyo in a suitable media over periods ranging from 18-144 hours;
- ii) subsequently inactivating the M.hyo culture;
- iii) harvesting the inactivated culture fluid, wherein the inactivated culture fluid comprises an M.hyo whole cell preparation comprising both a soluble liquid fraction and insoluble cellular material;
- iv) separating the soluble liquid fraction from the insoluble cellular material;
- v) substantially removing both IgG and antigen/immunoglobulin immunocomplexes from the separated soluble liquid fraction to form a soluble portion of the M.hyo whole cell preparation;
- and
- vi) subsequently combining the soluble portion of the M.hyo whole cell preparation with a PCV2 antigen and a Lawsonia intracellularis antigen.
Dependencies are inferred from the claim text.